All Posts

Stepping into 2026, the life sciences sector seems to be approaching with a sort of ‘confidence with guardrails’. Particularly coming out of the biggest, tone-setting event of the year, the JP Morgan Healthcare Conference. Comparatively speaking, the energy seemed more subdued, but not in a discouraging way. Progress and innovation messaging prevailed, despite the reportedly ‘slow start’ to the dealmaking there in San Francisco.

Thoughts on the assessment of risk and the ongoing need to embrace the power of commercial due diligence in a consistently volatile, fast-changing and increasingly dangerous new world order.

The Competitive landscape will not wait for you. Buyers change. Competitors reposition. Sales cycles compress. And yet many organizations are still relying on slow, reactive, or incomplete intelligence to guide critical decisions.